Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2014

View Archived Issues

New consortium to develop PDE inhibitors for neglected parasitic diseases

CalciMedica patent divulges novel Ca2+ channel modulators

Daiichi Sankyo and UCSF collaborate on drugs for neurodegenerative diseases

New murine models created to investigate type 1 hereditary hemorrhagic telangiectasia

US Oncology Research teams up with Corcept Therapeutics for mifepristone trial

MK-5172/MK-8742 combination effective in phase II C-WORTHY trial

Pfizer reports discovery of novel CRTH2 antagonists

Glenmark Pharmaceuticals' GRC-27864 enters human trials

Dyax receives FDA approval to expand the use of Kalbitor

Amgen reports topline results from phase III study of talimogene laherparepvec

Roche patent reports new FABP inhibitors

New BTK inhibitors designed by KBP BioSciences

ViiV Healthcare and MPP to improve access to dolutegravir

Scientists at Nanjing Sanhome Pharmaceutical disclose novel BCR-ABL1 inhibitors

Co-formulation of migalastat HCl and alpha-Gal A enhances stability and potency of the enzyme

Santen's SAKURA study meets primary endpoint in posterior segment uveitis

FDA approves Evzio for the emergency treatment of opioid overdose

MT-3724 shows significant antitumor activity in vitro and in vivo

Halozyme suspends enrollment and dosing in phase II trial of PEGPH-20 for pancreatic cancer

New START2 trial investigates tecemotide in stage III NSCLC

Genzyme to resubmit Lemtrada sBLA in U.S.

FDA extends PDUFA date for Afrezza review

Cellular Biomedicine initiates phase IIb trial of cell therapy for knee osteoarthritis

FDA awards breakthrough therapy designation to Bexsero

Preclinical efficacy of novel PDE10A inhibitors suggests potential for schizophrenia therapy

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...